ArticleStem cell reports2017
IAP-Based Cell Sorting Results in Homogeneous Transplantable Dopaminergic Precursor Cells Derived from Human Pluripotent Stem Cells.
Article in Stem cell reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05635409 (STEM-PD Trial), which is not on this map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
STEM-PD Trial: A Multicentre, Single Arm, First in Human, Dose-escalation Trial, Investigating the Safety and Tolerability of Intraputamenal Transplantation of Human Embryonic Stem Cell Derived Dopaminergic Cells for Parkinson's Disease (STEM-PD Product)
Who cites it
30 citing papers in PubMed, 48 citations in OpenAlex.
- Beyond phenotypic markers: rethinking dopaminergic identity in iPSC-derived neurons.Cell communication and signaling : CCS · 2026Review
- Stem cell treatments and Parkinson's disease: Science and misconceptions.Journal of Parkinson's disease · 2026Review
- The history and status of dopamine cell therapies for Parkinson's disease.BioEssays : news and reviews in molecular, cellular and developmental biology · 2024Review
- Article
- Current Status and Future Perspectives on Stem Cell-Based Therapies for Parkinson's Disease.Journal of movement disorders · 2023Article
- Neuronal cell-based medicines from pluripotent stem cells: Development, production, and preclinical assessment.Stem cells translational medicine · 2021Review
- Trophoblast glycoprotein is a marker for efficient sorting of ventral mesencephalic dopaminergic precursors derived from human pluripotent stem cells.NPJ Parkinson's disease · 2021Article
- Review
- Neural tube patterning: from a minimal model for rostrocaudal patterning toward an integrated 3D model.iScience · 2021Article
- Human stem cells harboring a suicide gene improve the safety and standardisation of neural transplants in Parkinsonian rats.Nature communications · 2021Article
- Gene therapy restores dopamine transporter expression and ameliorates pathology in iPSC and mouse models of infantile parkinsonism.Science translational medicine · 2021Article
- Mitomycin-C treatment during differentiation of induced pluripotent stem cell-derived dopamine neurons reduces proliferation without compromising survival or function in vivo.Stem cells translational medicine · 2021Article
- The potential therapy with dental tissue-derived mesenchymal stem cells in Parkinson's disease.Stem cell research & therapy · 2021Review
- The quest of cell surface markers for stem cell therapy.Cellular and molecular life sciences : CMLS · 2021Review
- Human autologous iPSC-derived dopaminergic progenitors restore motor function in Parkinson's disease models.The Journal of clinical investigation · 2020Article
- The future of stem cell therapies for Parkinson disease.Nature reviews. Neuroscience · 2020Review
- Peptide-Based Scaffolds for the Culture and Transplantation of Human Dopaminergic Neurons.Tissue engineering. Part A · 2020Article
- Current Status of Stem Cell-Derived Therapies for Parkinson's Disease: From Cell Assessment and Imaging Modalities to Clinical Trials.Frontiers in neuroscience · 2020Review
- Replacing what's lost: a new era of stem cell therapy for Parkinson's disease.Translational neurodegeneration · 2020Review
- Toward Generating Subtype-Specific Mesencephalic Dopaminergic NeuronsFrontiers in cell and developmental biology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human pluripotent stem cell (hPSC)-derived mesencephalic dopaminergic (mesDA) neurons can relieve motor deficits in animal models of Parkinson's disease (PD). Clinical translation of differentiation protocols requires standardization of production procedures, and surface-marker-based cell sorting is considered instrumental for reproducible generation of defined cell products. Here, we demonstrate that integrin-associated protein (IAP) is a cell surface marker suitable for enrichment of hPSC-derived mesDA progenitor cells. Immunomagnetically sorted IAP
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.